Impact of Chronic Kidney Disease on Use of Evidence-Based Therapy in Stable Coronary Artery Disease: A Prospective Analysis of 22,272 Patients

• Paul R. Kalra ,

  * E-mail: paulkalra@doctors.org.uk

  Affiliations Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom, NHLI Imperial College, ICMS, London, United Kingdom

  ⨯
• Xavier García-Moll,

  Affiliation Unitat Hospitalització, Servei de Cardiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

  ⨯
• José Zamorano,

  Affiliation University Hospital Ramón y Cajal, Madrid, Spain

  ⨯
• Philip A. Kalra,

  Affiliation Salford Royal NHS Foundation Trust, Salford, United Kingdom

  ⨯
• Kim M. Fox,

  Affiliations NHLI Imperial College, ICMS, London, United Kingdom, Royal Brompton Hospital, London, United Kingdom

  ⨯
• Ian Ford,

  Affiliation University of Glasgow, Glasgow, United Kingdom

  ⨯
• Roberto Ferrari,

  Affiliation Department of Cardiology, Azienda Ospedaliero-Universitaria di Ferrara, Ospedale di Cona, Cona, Italy

  ⨯
• Jean-Claude Tardif,

  Affiliation Montreal Heart Institute, Université de Montreal, Montreal, Canada

  ⨯
• Michal Tendera,

  Affiliation Medical University of Silesia, Katowice, Poland

  ⨯
• Nicola Greenlaw,

  Affiliation University of Glasgow, Glasgow, United Kingdom

  ⨯
• Ph. Gabriel Steg for the CLARIFY Investigators

  ¶Membership of the CLARIFY Investigators is included in Table S1.

  Affiliations Royal Brompton Hospital, London, United Kingdom, Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France, INSERM U-1148, Paris, France, Département Hospitalo-Universitaire FIRE, Hôpital Bichat, Assistance Publique – Hôpitaux de Paris, Paris, France

  ⨯